Working… Menu

Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04698915
Recruitment Status : Recruiting
First Posted : January 7, 2021
Last Update Posted : September 14, 2021
Information provided by (Responsible Party):
Galera Therapeutics, Inc.

Brief Summary:
GTI-4711-201 is designed as a Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the effect to OS by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline resectable nonmetastatic

Condition or disease Intervention/treatment Phase
SBRT Borderline Resectable Pancreatic Cancer Unresectable Pancreatic Cancer Drug: Drug GC4711 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 160 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: GRECO-2: A Randomized, Phase 2b Study of GC4711 in Combination With Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer
Actual Study Start Date : May 7, 2021
Estimated Primary Completion Date : October 2024
Estimated Study Completion Date : October 2027

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Arm A Active GC4711 Drug: Drug GC4711
15 Minute IV Infusion

Placebo Comparator: Arm B Placebo Drug: Placebo
15 Minute IV Infusion

Primary Outcome Measures :
  1. Median Overall Survival after SBRT completion [ Time Frame: From randomization up to 5 years ]

Secondary Outcome Measures :
  1. Median Progression Free Survival after SBRT Completion per RESIST 1.1 [ Time Frame: From randomization up to 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histological or biopsy proven adenocarcinoma of the pancreas. Cytology is acceptable if histology cannot be obtained.
  2. Newly diagnosed non-metastatic PC judged by tumor board to be feasible for (m)FOLFIRINOX and SBRT
  3. Remains non-metastatic (i.e., M0 disease) after 3 months of chemotherapy
  4. Female or male subjects ≥ 18 years of age
  5. ECOG performance status of 0-2
  6. Adequate end-organ function

Exclusion Criteria:

  1. Subjects with documented metastatic disease
  2. First-line chemotherapy other than (m)FOLFIRINOX and/or chemotherapy given for a total period of longer than 4 months prior to start of SBRT
  3. Prior abdominal RT with substantial overlap in radiation fields
  4. Subjects not recovered/controlled from treatment-related toxicities
  5. Uncontrolled malignancy other than PC
  6. Uncontrolled gastric or duodenal ulcer disease within 30 days of dosing
  7. Visible invasion of bulky tumor into the lumen of the bowel or stomach on endoscopy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04698915

Layout table for location contacts
Contact: Kara Terry 610-725-1500
Contact: Jon Holmlund, MD 610-725-1500

Layout table for location information
United States, Arizona
Banner MD Anderson Cancer Center Recruiting
Gilbert, Arizona, United States, 85234
Contact: Gary Walker, MD    480-878-2022      
Principal Investigator: Gary Walker, MD         
The University of Arizona Cancer Center Recruiting
Tucson, Arizona, United States, 85719
Contact: Uma Goyal, MD    520-694-2873      
Principal Investigator: Uma Goyal, MD         
United States, California
Cedars-Sinai Medical Center Recruiting
Los Angeles, California, United States, 90048
Contact: Mitchell Kamrava, MD    310-423-3277      
Principal Investigator: Mitchell Kamrava, MD         
United States, Iowa
University of Iowa Hospitals and Clinics Recruiting
Iowa City, Iowa, United States, 52242
Contact: Kellie Bodeker    319-384-6332      
Principal Investigator: Joseph Caster, MD         
United States, Michigan
Henry Ford Hospital Recruiting
Detroit, Michigan, United States, 48208
Contact: Parag Parikh, MD    313-916-2600      
Principal Investigator: Parag Parikh, MD         
United States, Ohio
University Hospitals of Cleveland Recruiting
Cleveland, Ohio, United States, 44106
Contact: Erin Anderson    216-844-8447      
Principal Investigator: Jennifer Dorth, MD         
United States, Oklahoma
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Jaclyn Arterburn    405-271-8001      
Principal Investigator: Sagila George, MD         
United States, Texas
UT Southwestern Medical Recruiting
Dallas, Texas, United States, 75390
Contact: Liliana Robles    215-645-4673      
Principal Investigator: Todd Aguilera, MD         
United States, Virginia
Blue Ridge Cancer Care Recruiting
Roanoke, Virginia, United States, 24014
Contact: Jessica Nichols    540-808-1704      
Principal Investigator: Mark Kochenderfer, MD         
Sponsors and Collaborators
Galera Therapeutics, Inc.
Layout table for investigator information
Study Chair: Jon Holmlund, MD Chief Medical Officer
Layout table for additonal information
Responsible Party: Galera Therapeutics, Inc. Identifier: NCT04698915    
Other Study ID Numbers: GTI-4711-201
First Posted: January 7, 2021    Key Record Dates
Last Update Posted: September 14, 2021
Last Verified: September 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases